TP53 and malignant colon neoplasm: Immunoreactivity for p53 was significantly reduced in colon cancer tissues compared to noncancer tissues, whereas SOCS2 immunoreactivity was enhanced in colon cancer tissues (n = 10, P < 0.01, Fig. 4b).